Releases › HCPCS Level II July 2025

HCPCS Level II July 2025

Effective 2025-07-01 to 2025-09-30. 8,770 codes in the release.

45added
4revised
17removed

Codes added 45

CodeDescription
C9174 Injection, datopotamab deruxtecan-dlnk, 1 mg
C9175 Injection, treosulfan, 50 mg
J0165 Injection, epinephrine, not otherwise specified, 0.1 mg
J0166 Injection, epinephrine (bpi), not therapeutically equivalent to j0165, 0.1 mg
J0167 Injection, epinephrine (hospira), not therapeutically equivalent to j0165, 0.1 mg
J0168 Injection, epinephrine (international medication systems), not therapeutically equivalent to j0165, 0.1 mg
J0169 Injection, epinephrine (adrenalin), not therapeutically equivalent to j0165, 0.1 mg
J0616 Injection, metoprolol tartrate, 1 mg
J0618 Injection, calcium chloride, 2 mg
J1163 Injection, diltiazem hydrochloride, 0.5 mg
J1326 Injection, zolbetuximab-clzb, 2 mg
J2312 Injection, naloxone hydrochloride, not otherwise specified, 0.01 mg
J2313 Injection, naloxone hydrochloride (zimhi), 0.01 mg
J3373 Injection, vancomycin hydrochloride, 10 mg
J3374 Injection, vancomycin hydrochloride (mylan) not therapeutically equivalent to j3373, 10 mg
J3375 Injection, vancomycin hydrochloride (xellia), not therapeutically equivalent to j3373, 10 mg
J3391 Injection, atidarsagene autotemcel, per treatment
J7172 Injection, marstacimab-hncq, 0.5 mg
J7356 Injection, foscarbidopa 0.25 mg/foslevodopa 5 mg
J9174 Injection, docetaxel (beizray), 1 mg
J9220 Injection, indigotindisulfonate sodium, 1 mg
J9275 Injection, cosibelimab-ipdl, 2 mg
J9276 Injection, zanidatamab-hrii, 2 mg
J9289 Injection, nivolumab, 2 mg and hyaluronidase-nvhy
J9341 Injection, thiotepa (tepylute), 1 mg
J9342 Injection, thiotepa, not otherwise specified, 1 mg
J9382 Injection, zenocutuzumab-zbco, 1 mg
Q2058 Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion
Q4368 Amchothick, per square centimeter
Q4369 Amnioplast 3, per square centimeter
Q4370 Aeroguard, per square centimeter
Q4371 Neoguard, per square centimeter
Q4372 Amchoplast excel, per square centimeter
Q4373 Membrane wrap lite, per square centimeter
Q4375 Duograft ac, per square centimeter
Q4376 Duograft aa, per square centimeter
Q4377 Trigraft ft, per square centimeter
Q4378 Renew ft matrix, per square centimeter
Q4379 Amniodefend ft matrix, per square centimeter
Q4380 Advograft one, per square centimeter
Q4382 Advograft dual, per square centimeter
Q5098 Injection, ustekinumab-srlf (imuldosa), biosimilar, 1 mg
Q5099 Injection, ustekinumab-stba (steqeyma), biosimilar, 1 mg
Q5100 Injection, ustekinumab-kfce (yesintek), biosimilar, 1 mg
Q5153 Injection, aflibercept-yszy (opuviz), biosimilar, 1 mg

Descriptions revised 4

CodeWas, and is now
C8005 Bronchoscopy, rigid or flexible, non-thermal transbronchial ablation of lesion(s) by pulsed electric field (pef) energy, including fluoroscopic and/or ultrasound guidance, when performed, with computed tomography acquisition(s) and 3d rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (ebus) guided transtracheal and/or transbronchial sampling (e.g., aspiration[s]/biopsy[ies]) of all mediastinal and/or hilar lymph node stations or structures, and therapeutic intervention(s) Bronchoscopy, rigid or flexible, non-thermal transbronchial ablation of lesion(s) by pulsed electric field (pef) energy, including fluoroscopic and/or ultrasound guidance, when performed, with computed tomography acquisition(s) and 3d rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (ebus) guided transtracheal and/or transbronchial sampling (e.g., aspiration[s]/biopsy[ies]) of lung(s) and all mediastinal and/or hilar lymph node stations or structures, and therapeutic intervention(s)
J1954 Injection, leuprolide acetate for depot suspension (cipla), 7.5 mg Injection, leuprolide acetate for depot suspension (lutrate depot), 7.5 mg
J9292 Injection, pemetrexed (avyxa), not therapeutically equivalent to j9305, 10 mg Injection, pemetrexed dipotassium, 10 mg
Q9998 Injection, ustekinumab-aekn (selarsdi), 1 mg Injection, ustekinumab-aekn (selarsdi), biosimilar, 1 mg

Terminated 17

CodeDescription
C9173 Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram
C9300 Injection, indigotindisulfonate sodium, 1 mg
C9301 Obecabtagene autoleucel, up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
C9302 Injection, zanidatamab-hrii, 2 mg
C9303 Injection, zolbetuximab-clzb, 1 mg
C9304 Injection, marstacimab-hncq, 0.5 mg
G9037 Interprofessional telephone/internet/electronic health record clinical question/request for specialty recommendations by a treating/requesting physician or other qualified health care professional for the care of the patient (i.e. not for professional education or scheduling) and may include subsequent follow up on the specialist's recommendations; 30 minutes
G9038 Co-management services with the following elements: new diagnosis or acute exacerbation and stabilization of existing condition; condition which may benefit from joint care planning; condition for which specialist is taking a co-management role; condition expected to last at least 3 months; comprehensive care plan established, implemented, revised or monitored in partnership with co-managing clinicians; ongoing communication and care coordination between co-managing clinicians furnishing care
J0171 Injection, adrenalin, epinephrine, 0.1 mg
J0173 Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg
J2310 Injection, naloxone hydrochloride, per 1 mg
J2311 Injection, naloxone hydrochloride (zimhi), 1 mg
J3370 Injection, vancomycin hcl, 500 mg
J3371 Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg
J3372 Injection, vancomycin hcl (xellia), not therapeutically equivalent to j3370, 500 mg
J9340 Injection, thiotepa, 15 mg
M0248 Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency